Belantamab mafodotin (belamaf) is a first‐in‐class, humanized antibody–drug conjugate (ADC) that binds B‐cell maturation antigen, a target expressed on malignant plasma cells in patients with MM, destroying MM cells through direct killing and immune response [4]. The gene discussed is PPIB; the disease is Miyoshi myopathy.